Clinical trial
The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in…
NCT00145691 · Sykehuset Innlandet HF, Other · Completed
Key facts
| NCT number | NCT00145691 |
|---|---|
| Title | The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) |
| Official title | The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) - An Eight Week Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi Center Trial. A Phase III Study |
| Lead sponsor | Sykehuset Innlandet HF, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Agitation Aggression in Dementia |
| Intervention type | Drug |
| Interventions | Oxcarbazepine |
| Enrollment | 100 |
| Start date | Sep 1, 2005 |
| Completion | Oct 1, 2006 |
| First posted | Sep 5, 2005 |
| Last update posted | Mar 21, 2007 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: